Goldenwell Biotech, Inc. reported a challenging financial performance for the fiscal year ending December 31, 2025, with revenues of only $55, a significant decrease from $139 in the previous year. The company's cost of revenue also declined to $43 from $75, resulting in a gross profit of $12, down from $64 in 2024. The net loss for the year was $296,471, compared to a loss of $131,498 in 2024, indicating a worsening financial situation. The company’s total liabilities increased to $379,833, while total stockholders' equity fell to $(343,713), reflecting ongoing financial difficulties.
In terms of operational changes, Goldenwell Biotech has not yet commenced commercial production of its products, which include various nutraceuticals and dietary supplements. The company has entered into exclusive patent license agreements with Australian Trefoil Health Technologies and Ji Lin JZY Biotech Inc. for the technology underlying its products. However, the company has not reported any significant product launches or acquisitions during the fiscal year. The company’s workforce remains minimal, with only three non-employee officers managing operations remotely.
The company’s operational metrics indicate a lack of customer engagement, as it has not generated substantial sales or user statistics. Goldenwell Biotech's cash and cash equivalents stood at $26,775 as of December 31, 2025, which the management believes is sufficient to support operations until at least the end of 2026. However, the company has expressed concerns about its ability to continue as a going concern, primarily due to its accumulated losses and the need for additional financing to support its business plan.
Looking ahead, Goldenwell Biotech aims to increase sales of its products and is exploring options for raising additional capital through debt or equity offerings. The company estimates that it requires approximately $5 million to establish manufacturing facilities and train its workforce, which it hopes to achieve within a year. However, there is no guarantee that the company will be able to secure the necessary funding, and management has cautioned that failure to do so could jeopardize its operations and future prospects.
About GOLDENWELL BIOTECH, INC.
Goldenwell Biotech, Inc. is an early-stage company focused on research, development, and production of nutraceuticals and dietary supplements. It licenses proprietary technology for health products, including peptides and plant extracts, targeting health-conscious consumers. The company operates with minimal assets, relies on external financing, and emphasizes innovation in bioactive health solutions within the wellness market.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.